BrainScan S.A. is executing an innovative project co-financed by the European Funds under the “European Funds for a Modern Economy” program (FENG), action “SMART Path”, application number: FENG.01.01-IP.02-002/23. The aim of the project is to research, develop, implement, and internationalize a significantly enhanced version of BrainScan CT – a multimodal system for automatic diagnosis support of pathological brain changes in computed tomography (CT). This next-generation medical AI solution leverages deep learning and advanced image analysis techniques to automatically detect and analyze critical brain abnormalities, with a special focus on primary and metastatic brain tumors, providing crucial support for radiologists and neurologists.
The system will also be optimized for the detection of other critical brain pathologies, including ischemic strokes, aneurysms, hemangiomas, vascular malformations, and vessel occlusions. With its advanced diagnostic capabilities, BrainScan CT aims to increase the speed, accuracy, and consistency of radiological assessments across global healthcare systems. By combining multimodal imaging analysis, clinical data integration, and AI-driven decision support, this project is set to become a breakthrough in medical diagnostics, helping doctors worldwide make faster and more accurate treatment decisions, ultimately improving patient outcomes.
Thanks to this project, BrainScan CT will evolve into the most comprehensive system in the world for the analysis of head CT scans. The inclusion of multiple diagnostic modules, high sensitivity for diverse neurological conditions, and continuous learning capabilities will ensure unmatched diagnostic coverage. This technological leap will position BrainScan S.A. as a global leader in neuroimaging AI, setting a new standard for automatic brain pathology detection and analysis.
